FDA panel backs Biosense Webster's catheter for atrial fibrillation
This article was originally published in Clinica
Executive Summary
A US FDA advisory panel has unanimously recommended approval of an ablation catheter developed by Biosense Webster for the treatment of atrial fibrillation (AF). The FDA is not required to follow the panel's advice, though it usually does.